Comparative effectiveness of peroxisome proliferator–activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis

PPAR agonists are effective second-line therapies for primary biliary cholangitis. Treatment ranking differences likely reflect variations in outcomes, populations, and drug mechanisms. In the absence of head-to-head trials, network meta-analysis provides important insights into comparative effectiveness. Further studies are warranted to confirm long-term safety and improve the evaluation of patient-centered outcomes.